Switch theme
Sign up to access all valuation multiples
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
1974
136
LTM Revenue $10.4M
Last FY EBITDA -$56.6M
$259M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Abeona Therapeutics has a last 12-month revenue (LTM) of $10.4M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Abeona Therapeutics achieved revenue of n/a and an EBITDA of -$56.6M.
Abeona Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Abeona Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $10.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $8.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 83% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$56.6M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$61.4M | XXX | -$64.2M | XXX | XXX | XXX |
| EBIT Margin | -591% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$48.0M | XXX | -$63.7M | XXX | XXX | XXX |
| Net Margin | -462% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Abeona Therapeutics's stock price is $6.
Abeona Therapeutics has current market cap of $319M, and EV of $259M.
See Abeona Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $259M | $319M | XXX | XXX | XXX | XXX | $-1.13 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Abeona Therapeutics has market cap of $319M and EV of $259M.
Abeona Therapeutics's trades at 74.0x EV/Revenue multiple, and -4.6x EV/EBITDA.
Equity research analysts estimate Abeona Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Abeona Therapeutics has a P/E ratio of -6.6x.
See valuation multiples for Abeona Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $319M | XXX | $319M | XXX | XXX | XXX |
| EV (current) | $259M | XXX | $259M | XXX | XXX | XXX |
| EV/Revenue | 24.9x | XXX | 74.0x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -4.6x | XXX | XXX | XXX |
| EV/EBIT | -4.2x | XXX | -4.0x | XXX | XXX | XXX |
| EV/Gross Profit | 30.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -6.6x | XXX | -5.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -4.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAbeona Therapeutics's last 12 month revenue growth is 469%
Abeona Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.5M for the same period.
Abeona Therapeutics's rule of 40 is -976% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Abeona Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Abeona Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 469% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -976% | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Abeona Therapeutics acquired XXX companies to date.
Last acquisition by Abeona Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Abeona Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Abeona Therapeutics founded? | Abeona Therapeutics was founded in 1974. |
| Where is Abeona Therapeutics headquartered? | Abeona Therapeutics is headquartered in United States of America. |
| How many employees does Abeona Therapeutics have? | As of today, Abeona Therapeutics has 136 employees. |
| Who is the CEO of Abeona Therapeutics? | Abeona Therapeutics's CEO is Mr. Vishwas Seshadri. |
| Is Abeona Therapeutics publicy listed? | Yes, Abeona Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Abeona Therapeutics? | Abeona Therapeutics trades under ABEO ticker. |
| When did Abeona Therapeutics go public? | Abeona Therapeutics went public in 1980. |
| Who are competitors of Abeona Therapeutics? | Similar companies to Abeona Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Abeona Therapeutics? | Abeona Therapeutics's current market cap is $319M |
| What is the current revenue of Abeona Therapeutics? | Abeona Therapeutics's last 12 months revenue is $10.4M. |
| What is the current revenue growth of Abeona Therapeutics? | Abeona Therapeutics revenue growth (NTM/LTM) is 469%. |
| What is the current EV/Revenue multiple of Abeona Therapeutics? | Current revenue multiple of Abeona Therapeutics is 24.9x. |
| Is Abeona Therapeutics profitable? | Yes, Abeona Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
